Pfizer, Hemophilia B
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration on Friday approved Pfizer’s treatment for a rare genetic bleeding disorder, making it the company’s first-ever gene therapy to win clearance in the U.S.
Pfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose
Pfizer's huge facility in Sanford produces its first FDA-approved gene therapy, which runs $3.5 million a dose.
FDA Approves Pfizer’s One-Time Gene Therapy BEQVEZ for Hemophilia B
The BEQVEZ gene therapy inserts a working copy of the Factor IX (FIX) gene that codes for a high-activity FIX variant.
Pfizer scores FDA nod for hemophilia B gene therapy, will charge $3.5M per dose
Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics, Pfizer has gained an FDA approval for the acquired treatment. | Ten years after dipping its toe into the gene therapy pool in a licensing deal with Spark Therapeutics,
Pfizer heralds “paradigm shift” in hemophilia B gene therapy with FDA approval
Pfizer's groundbreaking $3.5 million gene therapy for Hemophilia B just got FDA approval. Here’s what it means for patients and the future of medicine
FDA Approves Second Gene Therapy for Hemophilia B
Pfizer reported a list price of $3.5 million for its new gene therapy, Beqvez, for adults with this rare bleeding disorder.
U.S. FDA Approves Pfizer’s BEQVEZ™ (fidanacogene elaparvovec-dzkt), a One-Time Gene Therapy for Adults with Hemophilia B
Pfizer Inc. (NYSE: PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZ™ (fidanacogene elaparvovec-dzkt) for the
US FDA approves Pfizer's gene therapy for rare bleeding disorder
The U.S. Food and Drug Administration approved Pfizer's gene therapy for hemophilia B on Friday, the second such therapy for the rare bleeding disorder that typically requires regular infusions of a blood-clotting protein.
Pfizer's Beqvez Receives FDA Approval For Treatment Of Adults With Hemophilia B
Pfizer Inc. (PFE) announced that its gene therapy Beqvez also known as fidanacogene elaparvovec-dzkt has been approved by the
Pfizer’s First Gene Therapy Gets Approval for Clotting Disorder
Pfizer Inc. won US approval for its first gene therapy, expanding into a promising field of medicine that has proved to be a challenging business.
Becker's Hospital Review8d
FDA approves Pfizer's 1st gene therapy
Pfizer's first FDA-approved gene therapy is one of the most expensive medications in the U.S. On April 26, Beqvez (fidanacogene elaparvovec-dzkt) won approval to treat some adults with ...
The Business Journals8d
Pfizer gene therapy made in NC gets FDA approval. It costs $3.5M per dose
The U.S. Food and Drug Administration has approved a gene therapy developed by Pfizer and manufactured at the company's massive North Carolina facility. Pfizer (NYSE: PFE) on Friday ...
NBC Washington11d
FDA approves Pfizer's first gene therapy for rare inherited bleeding disorder
The Food and Drug Administration approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency ...